StonvexLoading…
StonvexStonvexStonvexCore line items from TBI's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-28 | Annual 2024 2024-12-29 | Annual 2023 2023-12-31 | Annual 2022 2022-12-25 |
|---|---|---|---|---|
Revenue | $1.62B | $1.57B | $1.91B | $2.25B |
Operating Income | $-46.63M | $-92.78M | $-23.85M | $72.19M |
Net Income | $-47.96M | $-125.75M | $-14.17M | $62.27M |
EPS (Diluted) | $-1.61 | $-4.17 | $-0.45 | $1.86 |
Total Assets | $638.67M | $675.38M | $899.38M | $1.02B |
Total Liabilities | $364.11M | $360.02M | $441.51M | $523.09M |
Cash & Equivalents | $24.51M | $22.54M | $61.88M | $72.05M |
Free Cash Flow OCF − CapEx | $-73.72M | $-41.21M | $3.48M | $89.88M |
Shares Outstanding | 29.99M | 29.59M | 31.25M | 32.73M |